Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

764
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
764
Visual Agnosia01:12

Visual Agnosia

475
Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round...
475
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

305
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
305
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

6.8K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.8K
Prosopagnosia01:24

Prosopagnosia

395
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
395
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

392
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Journal of neurology·2026
Same author

Functional imaging constrained diffusion for brain PET synthesis from structural MRI.

Medical image analysis·2026
Same author

Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial.

JAMA neurology·2026
Same author

Cerebral Blood and Cerebrospinal Fluid Flow Dynamics in Endurance Athletes: Associations With Aortic Recoil and Heart Rate.

Scandinavian journal of medicine & science in sports·2026
Same author

Plasma p-tau217 and <i>APOE</i> genotype: Prodromal Alzheimer's disease staging.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Coupling between global brain blood oxygen level-dependent activity and cerebrospinal fluid dynamics in young endurance athletes.

Experimental physiology·2026
Same journal

Impaired pathways of detoxification and risk of Alzheimer's disease: Differential gene expression studies via gene set expression analysis.

Journal of Alzheimer's disease reports·2026
Same journal

Instrument for Assessment of Neurodegenerative Aphasia in Indonesia or <i>Instrumen Afasia Neurodegeneratif Indonesia</i> (IRFANI): Development and pilot study.

Journal of Alzheimer's disease reports·2026
Same journal

Probing cognitive reserve with resting state functional connectivity in subcortical ischemic vascular cognitive impairment.

Journal of Alzheimer's disease reports·2026
Same journal

Unraveling the impact of common medications on biomarker patterns in Alzheimer's disease and mild cognitive impairment.

Journal of Alzheimer's disease reports·2026
Same journal

Identification of novel serum biomarkers for Alzheimer's disease screened by phage display library of random peptides.

Journal of Alzheimer's disease reports·2026
Same journal

Estimates of current capacity for diagnosing and implementation of new treatment Alzheimer's disease in Slovenia.

Journal of Alzheimer's disease reports·2026
See all related articles

Related Experiment Video

Updated: Oct 20, 2025

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

21.8K

Alzheimer's Disease Progressively Reduces Visual Functional Network Connectivity.

Jie Huang1, Paul Beach2, Andrea Bozoki1,3,4

  • 1Department of Radiology, Michigan State University, East Lansing, MI, USA.

Journal of Alzheimer'S Disease Reports
|September 13, 2021
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) severity impacts visual networks, reducing connectivity more with cognitive decline. This disruption, particularly in face processing, may predict AD progression.

Keywords:
Alzheimer’s diseaseFAUPAface-evoked visual-processing networkfunctional areas of unitary pooled activityresting-state visual functional connectivity network

More Related Videos

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.1K
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.0K

Related Experiment Videos

Last Updated: Oct 20, 2025

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

21.8K
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.1K
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.0K

Area of Science:

  • Neuroscience
  • Medical Imaging
  • Neurology

Background:

  • Alzheimer's disease (AD) pathology progresses sequentially through visual cortical areas.
  • Postmortem studies reveal amyloid-beta and neurofibrillary tangles in the visual cortex.

Purpose of the Study:

  • Investigate how Alzheimer's disease severity affects visual functional networks.
  • Examine the impact of AD on resting-state and task-based visual processing networks.

Main Methods:

  • Used resting-state fMRI (rs-fMRI) and task fMRI in severe AD, mild/moderate AD, and healthy senior groups.
  • Identified resting-state visual functional connectivity (FC) and face-evoked visual-processing networks.

Main Results:

  • AD severity-dependently reduced connectivity in both visual networks.
  • Mild/moderate AD disrupted higher-order visual areas; severe AD affected lower-order areas.
  • Face-evoked network disruption correlated with cognitive impairment severity.

Conclusions:

  • Findings support the sequential progression of AD pathology in visual areas.
  • Disruption of visual networks, especially face processing, may serve as an AD progression biomarker.